Prelude Therapeutics
NEWARK, DE · Founded 2016 · CIK 0001678660 · Biotech · Private
Selective small-molecule degraders and inhibitors targeting cancer-driving proteins
preludetx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $97M
- 4 Form D · Aug 2020
- 73 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 8 granted · 32 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,000,000 | |
| Private capital raised | Form D · SEC | $12,000,000 | |
| Private capital raised | Form D · SEC | $29,999,999 | |
| Private capital raised | Form D · SEC | $49,999,969 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2830 | JUNIPERO THERAPEUTICS, INC. | — | — |
| 2831 | Inceptive Nucleics, Inc. | — | $100M |
| 2832 | Arena Pharmaceuticals | — | $187M |
| 2833 | Prelude Therapeutics | — | $97M |
| 2834 | Coriell Life Sciences, Inc. | — | $10M |
| 2835 | Tango Therapeutics | — | $95M |
| 2836 | Arcutis Biotherapeutics, Inc. | — | $94M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- David BonitaDirector
- Andrew CombsExecutive Officer
- Mardi DierDirector
- Paul FriedmanDirector
- Juan LuengoExecutive Officer
- David MauroExecutive Officer
- Deborah MorosiniExecutive Officer
- Kelvin NeuDirector
- Christopher PierceExecutive Officer
- Brian PiperExecutive Officer
- Victor SandorDirector
- Peggy ScherleExecutive Officer
- Krishna VaddiDirector · Executive Officer
Patents
- JAK2 Inhibitors And Their Use As Pharmaceuticalsapplication
- KAT6 Targeting Compoundsapplication
- KAT6 Targeting Compoundsapplication
- Combination Treatment Regimens - SMARCA2 Degrader With Taxane Anticancer Agentapplication
- Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)application
- CDK Inhibitors And Their Use As Pharmaceuticalsgranted
- Processes For Making PRMT5 Inhibitorsapplication
- Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)granted
- BRM Targeting Compounds And Associated Methods Of Usegranted
- Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)granted
- Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)granted
- CDK Inhibitors And Their Use As Pharmaceuticalsapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.